Daiichi Sankyo Company Limited (DSKYF.PK) News Headlines

▮ More

Date

Headline

9/20/2021 2:29:16 AM AstraZeneca: Enhertu Triples Progression-free Survival In Phase III DESTINY-Breast03 Trial

8/9/2021 2:46:10 AM AstraZeneca : Enhertu Improves PFS In Phase 3 Trial On Metastatic Breast Cancer

4/27/2021 5:52:09 AM Daiichi Sankyo FY20 Profit Down; Sees Higher Operating Profit, Revenues In FY21

4/27/2021 5:09:16 AM Daiichi Sankyo FY EPS 39.11 Yen Vs 66.27 Yen Last Year

1/20/2021 2:30:49 AM AstraZeneca And Daiichi Sankyo's Enhertu Approved In EU For Breast Cancer

1/18/2021 3:00:48 AM AstraZeneca, Daiichi Sankyo: Enhertu Gets US Approval For HER2-positive Advanced Gastric Cancer

1/18/2021 2:03:37 AM AstraZeneca And Daiichi Sankyo Announce Enhertu Approved In The US For Gastric Cancer

12/16/2020 4:35:03 AM Daiichi Sankyo, Esperion Report Swissmedic Approval For NILEMDO & NUSTENDI

12/14/2020 8:48:52 AM Daiichi Sankyo And AstraZeneca Announce Initiation Of TROPION-Lung01

12/10/2020 8:02:42 AM AstraZeneca, Daiichi Sankyo: ENHERTU Demonstrated Durable Responses In Phase II Trial

7/27/2020 2:22:11 AM AstraZeneca In Deal To Develop, Commercialise Daiichi Sankyo's DS-1062 For Upfront Payment Of $1 Bln

7/27/2020 2:02:47 AM AstraZeneca And Daiichi Sankyo Enter Collaboration To Develop DS-1062

5/29/2020 8:41:39 AM AstraZeneca : Phase II DESTINY-CRC01 Trial Shows Clinically Meaningful Activity In Colorectal Cancer

5/22/2020 2:49:55 AM AstraZeneca: FDA Grants Orphan Drug Designation To Enhertu For Gastric Cancer

5/18/2020 2:22:16 AM Enhertu Granted BTD In US For HER2-mutant Metastatic Non-small Cell Lung Cancer

5/11/2020 3:10:44 AM AstraZeneca: FDA Grants Second Breakthrough Therapy Designation To Enhertu

5/7/2020 8:15:20 AM Daiichi Sankyo Submits SNDA To Japan's MHLW For Trastuzumab Deruxtecan

1/27/2020 2:35:54 AM AstraZeneca: Brilinta, Enhertu Met Primary Endpoint In Respective Trials

1/27/2020 2:07:43 AM AstraZeneca: Phase II DESTINY-Gastric01 Trial Of Enhertu Vs Chemotherapy Met Primary Endpoint

Older Articles